Aspira Women’s Health announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President effective April 1, 2024. Dr. Milligan will report to Nicole Sandford, who will remain CEO. The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry. Dr. Milligan is an accomplished and proven leader with 25+ years of experience in the healthcare sector, with corporate experience that includes executive roles of increasing responsibility at innovative biopharmaceutical companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AWH:
- Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
- Aspira Women’s Health announces OvaSuite distribution agreement in Philippines
- Aspira price target raised to $7.20 from $5.65 at Alliance Global
- Aspira Women’s Health Adjusts Warrant Terms Post-Split
- Aspira Women’s Health Executes Private Equity Placement
